Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia

被引:49
|
作者
Shaarawy, M
ElDidy, H
机构
[1] Dept. of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo
关键词
fibronectin; plasminogen activator inhibitor type 1; thrombomodulin; preeclampsia; eclampsia;
D O I
10.1016/S0020-7292(96)02755-5
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Preeclampsia has been recently suggested to be an endothelial cell disorder. This study was initiated to determine the levels of various biomarkers of endothelial damage in preeclampsia and eclampsia. Methods: Blood samples were withdrawn from 70 pregnant women in their third trimester grouped as 25 mild preeclampsia, 15 severe preeclampsia, 10 eclampsia and 20 normotensive healthy women (controls) for the determination of thrombomodulin by ELISA, PAI-1 by urokinase method and fibronectin by radial immunodiffusion. Results were statistically analyzed by Student's t-test. Results: Circulation levels of PAI-1, thrombomodulin and fibronectin were increased with increasing severity of the disease. Thrombomodulin was the only parameter which did not change significantly in mild preeclampsia. The average percent increments in preeclampsia and eclampsia were 63%, 102% and 132%, respectively. Conclusions: These results demonstrate that fibronectin may be a more valuable biomarker than thrombomodulin and PAI-I for the assessment of endothelial damage in preeclampsia and eclampsia.
引用
收藏
页码:135 / 139
页数:5
相关论文
共 50 条
  • [31] Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in diabetic foot syndrome
    Kulwas, Arleta
    Lisewska, Beata
    Jundzill, Wieslaw
    Ruszkowska, Barbara
    Drewniak, Wanda
    Ruprecht, Zofia
    Gadomska, Grazyna
    Rosc, Danuta
    ADVANCES IN MEDICAL SCIENCES, 2017, 62 (01): : 87 - 91
  • [32] An unexpected role of plasminogen activator inhibitor-type 1 (PAI-1) in renal fibrosis
    Huang, YF
    Noble, N
    KIDNEY INTERNATIONAL, 2005, 67 (06) : 2502 - 2503
  • [33] Increased plasminogen activator inhibitor type-1 (PAI-1) in the heart as a function of age
    Sobel, Burton E.
    Lee, Yong-Ho
    Pratley, Richard E.
    Schneider, David J.
    LIFE SCIENCES, 2006, 79 (17) : 1600 - 1605
  • [34] Generation and characterization of endothelial cells transduced with plasminogen activator inhibitor-1 (PAI-1) or vitronectin
    Schar, CR
    Sackman, JE
    Peterson, CB
    THROMBOSIS AND HAEMOSTASIS, 1999, : 810 - 810
  • [35] ACTIVATION OF HUMAN-ENDOTHELIAL TYPE PLASMINOGEN-ACTIVATOR INHIBITOR (PAI-1) BY NEGATIVELY CHARGED PHOSPHOLIPIDS
    LAMBERS, JWJ
    CAMMENGA, M
    KONIG, B
    PANNEKOEK, H
    VANMOURIK, JA
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 2 - 2
  • [36] ON THE KINETICS OF THE INHIBITION OF PLASMINOGEN ACTIVATORS BY THE PLASMINOGEN-ACTIVATOR INHIBITOR PAI-1
    CHMIELEWSKA, J
    WIMAN, B
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 3 - 3
  • [37] Downregulation of urokinase-type plasminogen activator inhibitor (PAI-1) in pancreatic cancer
    Metzger, R.
    Warnecke-Eberz, U.
    Prenzel, K. L.
    Baldus, S. E.
    Brabender, J.
    Vallboehmer, D.
    Hoelscher, A. H.
    Schneider, P. M.
    EJC SUPPLEMENTS, 2006, 4 (06): : 27 - 27
  • [38] A novel role for type I plasminogen activator inhibitor (PAI-1) in type II diabetes
    Randa, Gina M.
    Profozich, Jennifer L.
    Olshanski, Anne
    Garcia-Ocana, Adolfo
    Mars, Wendy M.
    Piganelli, Jon D.
    DIABETES, 2006, 55 : A614 - A614
  • [39] ROLE OF PLASMINOGEN ACTIVATOR INHIBITOR -1 (PAI-1) IN CANCER STEM CELLS
    Irmak-Yazicioglu, M. B.
    Ergun, K.
    WORLD CANCER RESEARCH JOURNAL, 2022, 9
  • [40] Plasminogen-activator inhibitor-1 in (PAI-1) gastric cancer
    Tabuchi, Y
    Nakamura, T
    Miyamura, K
    Nakae, S
    PROGRESS IN GASTRIC CANCER RESEARCH 1997: PROCEEDINGS OF THE 2ND INTERNATIONAL GASTRIC CANCER CONGRESS, 1997, : 447 - 450